{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:43:02Z","timestamp":1774953782362,"version":"3.50.1"},"reference-count":68,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>The potential relationship between obesity and colorectal cancer (CRC) outcome is poorly understood in patients with late-stage disease. Increased body mass index may negate aspirin use for cancer prevention, but its role as a factor on the effectiveness of postdiagnosis aspirin use is unclear.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate how prediagnosis obesity and postdiagnosis aspirin use may be associated with overall survival in patients with late-stage colorectal cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study used self-reported data from patients with metastatic or treatment-refractory disease who consented to a clinical protocol at MD Anderson Cancer Center, a large US cancer treatment center. Patients were enrolled between 2010 and 2018 and followed up for mortality through July 2020. Analyses were conducted through March 2022.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Body mass index in the decade prior to initial diagnosis and regular aspirin use at survey completion.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Overall survival was measured from stage IV diagnosis until death or last follow-up. Cox proportional hazards models were constructed to estimate associations of prediagnosis obesity and postdiagnosis aspirin use with overall survival.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 656 patients included in this analysis, 280 (42.7%) were women, 135 (20.6%) were diagnosed with CRC before age 45 years, 414 (63.1%) were diagnosed between ages 45 and 65 years, and 107 (16.3%) were diagnosed at 65 years or older; 105 patients (16.0%) were Black or Hispanic, and 501 (76.4%) were non-Hispanic White. Controlling for age, sex, race, stage at initial diagnosis, and weight change between prediagnosis and survey date, patients with obesity in the decade prior to CRC diagnosis had significantly higher likelihood of death (hazard ratio, 1.45; 95% CI, 1.11-1.91) compared with those with normal prediagnosis body mass index. Furthermore, only patients with normal prediagnosis body mass index experienced significant survival benefit with postdiagnosis aspirin use (hazard ratio, 0.59; 95% CI, 0.39-0.90).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cross-sectional study, our findings suggest potentially differential tumor development in the long-term physiologic host environment of obesity. Confirmation and further evaluation are needed to determine whether prediagnosis body mass index may be used to estimate the benefit from postdiagnosis aspirin use.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2022.36357","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T15:34:04Z","timestamp":1665761644000},"page":"e2236357","source":"Crossref","is-referenced-by-count":4,"title":["Association of Prediagnosis Obesity and Postdiagnosis Aspirin With Survival From Stage IV Colorectal Cancer"],"prefix":"10.1001","volume":"5","author":[{"given":"Jennifer S.","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Department of Cancer Biology, University of Kansas Medical Center, Kansas City"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janelle C.","family":"Chavez","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Cancer Prevention Research Training Program, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Stanford University School of Medicine, Stanford, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Kok","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Cancer Prevention Research Training Program, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Baylor College of Medicine, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazmin","family":"San Miguel","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Cancer Prevention Research Training Program, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Abbott Laboratories, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwa Young","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Cancer Prevention Research Training Program, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry","family":"Henderson","sequence":"additional","affiliation":[{"name":"Department of Cancer Prevention Research Training Program, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Foundation Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Van","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Kee","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fogelman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Merck & Co, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailesh M.","family":"Advani","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Terasaki Institute of Biomedical Innovation, Los Angeles, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benny","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Parseghian","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenna R.","family":"Shaw","sequence":"additional","affiliation":[{"name":"Department of Sheikh Khalifa Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Vilar","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanwal P.","family":"Raghav","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imad","family":"Shureiqi","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Now with Department of Cancer Biology, University of Michigan Medical School, Ann Arbor"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Funda","family":"Meric-Bernstam","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dipen","family":"Maru","sequence":"additional","affiliation":[{"name":"Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Menter","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shine","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Cancer Prevention Research Training Program, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"issue":"1","key":"zoi221027r2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014.","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"zoi221027r3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1136\/gut.2005.068189","article-title":"Effect of physical activity and body size on survival after diagnosis with colorectal cancer.","volume":"55","author":"Haydon","year":"2006","journal-title":"Gut"},{"issue":"19","key":"zoi221027r4","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1093\/jnci\/84.19.1491","article-title":"Risk factors for fatal colon cancer in a large prospective study.","volume":"84","author":"Thun","year":"1992","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"zoi221027r5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.7326\/0003-4819-122-5-199503010-00002","article-title":"Physical activity, obesity, and risk for colon cancer and adenoma in men.","volume":"122","author":"Giovannucci","year":"1995","journal-title":"Ann Intern Med"},{"issue":"8","key":"zoi221027r6","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrc1408","article-title":"Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.","volume":"4","author":"Calle","year":"2004","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"zoi221027r7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/cac2.v41.11","article-title":"A global assessment of recent trends in gastrointestinal cancer and lifestyle-associated risk factors.","volume":"41","author":"Lu","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"30","key":"zoi221027r8","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1200\/JCO.2016.67.4473","article-title":"Metabolic dysfunction, obesity, and survival among patients with early-stage colorectal cancer.","volume":"34","author":"Cespedes Feliciano","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi221027r9","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1093\/aje\/152.9.847","article-title":"Body mass index and colon cancer mortality in a large prospective study.","volume":"152","author":"Murphy","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"8","key":"zoi221027r10","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/cncr.27938","article-title":"Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.","volume":"119","author":"Sinicrope","year":"2013","journal-title":"Cancer"},{"issue":"3","key":"zoi221027r11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma.","volume":"98","author":"Meyerhardt","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"zoi221027r12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.2004.07.121","article-title":"Impact of body mass index on outcomes and treatment-related toxicity in patients with stage II and III rectal cancer: findings from Intergroup Trial 0114.","volume":"22","author":"Meyerhardt","year":"2004","journal-title":"J Clin Oncol"},{"issue":"22","key":"zoi221027r13","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1093\/jnci\/djj442","article-title":"Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.","volume":"98","author":"Dignam","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"zoi221027r14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1200\/JCO.2011.38.0287","article-title":"Impact of body mass index on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort.","volume":"30","author":"Campbell","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi221027r15","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1158\/1078-0432.CCR-09-2636","article-title":"Obesity is an independent prognostic variable in colon cancer survivors.","volume":"16","author":"Sinicrope","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"5","key":"zoi221027r16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation.","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"8","key":"zoi221027r17","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1007\/s11605-015-2834-z","article-title":"Visceral obesity predicts fewer lymph node metastases and better overall survival in colon cancer.","volume":"19","author":"Park","year":"2015","journal-title":"J Gastrointest Surg"},{"issue":"11","key":"zoi221027r18","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1586\/17474124.2015.1089170","article-title":"Is obesity an advantage in patients with colorectal cancer?","volume":"9","author":"Kasi","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10","key":"zoi221027r19","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s10552-006-0075-x","article-title":"Aspirin may be more effective in preventing colorectal adenomas in patients with higher BMI (United States).","volume":"17","author":"Kim","year":"2006","journal-title":"Cancer Causes & Control"},{"issue":"4","key":"zoi221027r20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1053\/j.seminoncol.2011.05.007","article-title":"Beyond standard adjuvant therapy for colon cancer: role of nonstandard interventions.","volume":"38","author":"Meyerhardt","year":"2011","journal-title":"Semin Oncol"},{"issue":"8","key":"zoi221027r21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/jnci\/djk132","article-title":"A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence.","volume":"99","author":"Jacobs","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"zoi221027r22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/nrclinonc.2011.199","article-title":"The role of aspirin in cancer prevention.","volume":"9","author":"Thun","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"zoi221027r23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1056\/NEJMoa021735","article-title":"A randomized trial of aspirin to prevent colorectal adenomas.","volume":"348","author":"Baron","year":"2003","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi221027r24","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa021633","article-title":"A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.","volume":"348","author":"Sandler","year":"2003","journal-title":"N Engl J Med"},{"issue":"9754","key":"zoi221027r25","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(10)61543-7","article-title":"Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials.","volume":"376","author":"Rothwell","year":"2010","journal-title":"Lancet"},{"issue":"6","key":"zoi221027r26","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1001\/jamaoncol.2015.6396","article-title":"Population-wide impact of long-term use of aspirin and the risk for cancer.","volume":"2","author":"Cao","year":"2016","journal-title":"JAMA Oncol"},{"issue":"9573","key":"zoi221027r27","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/S0140-6736(07)60747-8","article-title":"Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies.","volume":"369","author":"Flossmann","year":"2007","journal-title":"Lancet"},{"issue":"3","key":"zoi221027r28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nrc.2016.4","article-title":"Aspirin and colorectal cancer: the promise of precision chemoprevention.","volume":"16","author":"Drew","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"zoi221027r29","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1002\/cncr.v115:24","article-title":"Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis.","volume":"115","author":"Zell","year":"2009","journal-title":"Cancer"},{"issue":"16","key":"zoi221027r30","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jnci\/djs318","article-title":"Daily aspirin use and cancer mortality in a large US cohort.","volume":"104","author":"Jacobs","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"zoi221027r31","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1136\/gutjnl-2014-308260","article-title":"Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis.","volume":"64","author":"Li","year":"2015","journal-title":"Gut"},{"issue":"5","key":"zoi221027r32","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1056\/NEJMra040958","article-title":"Systemic therapy for colorectal cancer.","volume":"352","author":"Meyerhardt","year":"2005","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi221027r33","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/bjc.2014.481","article-title":"Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies.","volume":"111","author":"Ye","year":"2014","journal-title":"Br J Cancer"},{"issue":"4","key":"zoi221027r34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152402","article-title":"Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies.","volume":"11","author":"Elwood","year":"2016","journal-title":"PLoS One"},{"issue":"9826","key":"zoi221027r35","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(12)60209-8","article-title":"Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials.","volume":"379","author":"Rothwell","year":"2012","journal-title":"Lancet"},{"issue":"9759","key":"zoi221027r36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials.","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"zoi221027r37","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrclinonc.2012.137","article-title":"Aspirin as adjuvant therapy for colorectal cancer\u2013reinterpreting paradigms.","volume":"9","author":"Chia","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"zoi221027r38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/nrclinonc.2012.216","article-title":"Potential biomarker for aspirin use in colorectal cancer therapy.","volume":"10","author":"Langley","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"zoi221027r39","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1200\/JCO.2016.70.7547","article-title":"Aspirin use and colorectal cancer survival according to tumor CD274 (programmed cell death 1 ligand 1) expression status.","volume":"35","author":"Hamada","year":"2017","journal-title":"J Clin Oncol"},{"issue":"34","key":"zoi221027r40","doi-asserted-by":"publisher","first-page":"4297","DOI":"10.1200\/JCO.2013.50.0322","article-title":"Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer.","volume":"31","author":"Domingo","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi221027r41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.clon.2015.11.008","article-title":"PIK3CA mutation, aspirin use after diagnosis and survival of colorectal cancer. a systematic review and meta-analysis of epidemiological studies.","volume":"28","author":"Paleari","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"zoi221027r42","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3109\/0284186X.2014.990158","article-title":"Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation.","volume":"54","author":"Kothari","year":"2015","journal-title":"Acta Oncol"},{"issue":"4","key":"zoi221027r43","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2017.18","article-title":"Evaluation of PTGS2 expression, PIK3CA mutation, aspirin use and colon cancer survival in a population-based cohort study.","volume":"8","author":"Gray","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"zoi221027r44","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/imj.13312","article-title":"Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.","volume":"47","author":"Murphy","year":"2017","journal-title":"Intern Med J"},{"issue":"34","key":"zoi221027r45","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1200\/JCO.2013.52.0080","article-title":"Aspirin therapy for colorectal cancer with PIK3CA mutation: simply complex!","volume":"31","author":"Fuchs","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10145","key":"zoi221027r46","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0140-6736(18)31133-4","article-title":"Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials.","volume":"392","author":"Rothwell","year":"2018","journal-title":"Lancet"},{"issue":"6127","key":"zoi221027r47","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes.","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"6","key":"zoi221027r48","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/annonc\/mdw073","article-title":"Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.","volume":"27","author":"Overman","year":"2016","journal-title":"Annals Oncol"},{"issue":"8","key":"zoi221027r49","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1017\/S0007114517000952","article-title":"Evaluation of diet pattern and weight gain in postmenopausal women enrolled in the Women\u2019s Health Initiative Observational Study.","volume":"117","author":"Ford","year":"2017","journal-title":"Br J Nutr"},{"issue":"13","key":"zoi221027r50","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1200\/JCO.2016.71.9807","article-title":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.","volume":"35","author":"Sepulveda","year":"2017","journal-title":"J Clin Oncol"},{"key":"zoi221027r51","doi-asserted-by":"crossref","article-title":"Regression models and life-tables.","author":"Cox","DOI":"10.1007\/978-1-4612-4380-9_37"},{"key":"zoi221027r52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12874-016-0130-6","article-title":"Mechanisms and mediation in survival analysis: towards an integrated analytical framework.","volume":"16","author":"Pratschke","year":"2016","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"zoi221027r54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120706","article-title":"Association between body mass index and prognosis of colorectal cancer: a meta-analysis of prospective cohort studies.","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"issue":"11","key":"zoi221027r55","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10552-014-0450-y","article-title":"Association of obesity and overweight with overall survival in colorectal cancer patients: a meta-analysis of 29 studies.","volume":"25","author":"Wu","year":"2014","journal-title":"Cancer Causes & Control"},{"issue":"16","key":"zoi221027r56","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1158\/0008-5472.CAN-18-0326","article-title":"Influence of smoking, body mass index, and other factors on the preventive effect of nonsteroidal anti-inflammatory drugs on colorectal cancer risk.","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"issue":"10","key":"zoi221027r57","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.cgh.2014.03.021","article-title":"Measures of adiposity are associated with increased risk of peptic ulcer.","volume":"12","author":"Boylan","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"13","key":"zoi221027r58","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.119.044142","article-title":"No modulation of the effect of aspirin by body weight in healthy older men and women.","volume":"141","author":"Woods","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"zoi221027r59","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/bjc.2016.425","article-title":"Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study.","volume":"116","author":"Frouws","year":"2017","journal-title":"Br J Cancer"},{"issue":"1","key":"zoi221027r60","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s12885-018-4142-y","article-title":"Low-dose aspirin use and survival in colorectal cancer: results from a population-based cohort study.","volume":"18","author":"Gray","year":"2018","journal-title":"BMC Cancer"},{"issue":"6","key":"zoi221027r61","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jama.2009.1112","article-title":"Aspirin use and survival after diagnosis of colorectal cancer.","volume":"302","author":"Chan","year":"2009","journal-title":"JAMA"},{"issue":"5","key":"zoi221027r62","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ijc.30163","article-title":"Relationship of prediagnostic body mass index with survival after colorectal cancer: stage-specific associations.","volume":"139","author":"Kocarnik","year":"2016","journal-title":"Int J Cancer"},{"issue":"17","key":"zoi221027r63","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/cncr.29440","article-title":"Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer.","volume":"121","author":"Shah","year":"2015","journal-title":"Cancer"},{"issue":"8","key":"zoi221027r64","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/jth.12637","article-title":"Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action.","volume":"12","author":"Patrignani","year":"2014","journal-title":"J Thromb Haemost"},{"issue":"1","key":"zoi221027r65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1517\/17425255.2014.971010","article-title":"Competition between low-dose aspirin and other NSAIDs for COX-1 binding and its clinical consequences for the drugs\u2019 antiplatelet effects.","volume":"11","author":"Stepensky","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"zoi221027r66","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkaa024","article-title":"Body mass index and weight loss in metastatic colorectal cancer in CALGB (Alliance)\/SWOG 80405.","volume":"4","author":"Guercio","year":"2020","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"1","key":"zoi221027r67","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/ijc.v150.1","article-title":"Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized Phase III trial FIRE-3 (AIO KRK-0306).","volume":"150","author":"Liu","year":"2022","journal-title":"Int J Cancer"},{"issue":"10","key":"zoi221027r68","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1111\/obr.v20.10","article-title":"Validity of self-reported recall of anthropometric measures in early life: a systematic review and meta-analysis.","volume":"20","author":"De Rubeis","year":"2019","journal-title":"Obes Rev"},{"key":"zoi221027r53","volume-title":"Mplus User's Guide","author":"Muthen","year":"1998-2012","edition":"Seventh Edition"},{"key":"zoi221027r1","unstructured":"American Cancer Society. Colorectal Cancer Facts & Figures 2020-2022. Published 2020. Accessed March 10, 2020. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/colorectal-cancer-facts-and-figures\/colorectal-cancer-facts-and-figures-2020-2022.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2797320\/davis_2022_oi_221027_1664988099.29607.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T15:34:14Z","timestamp":1665761654000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2797320"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":68,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36357","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]}}}